The Supervisory Board of Medios AG has appointed Thomas Meier as the new Chief Executive Officer effective February 1, 2026, marking a strategic leadership transition for the German specialty pharmaceutical company. Meier succeeds Matthias Gaertner, who will remain in office until December 31, 2025, concluding a ten-year tenure that significantly shaped Medios' growth trajectory.
This leadership change carries substantial implications for Medios' position in the European Specialty Pharma market, particularly as the company focuses on expanding individualized medicine solutions. Meier brings extensive international experience from his current role as CEO of Swiss Contract Development and Manufacturing Organization Bachem Holding AG, a publicly traded company where he has led since 2020. His background includes previous positions as Chief Operations Officer at Bachem and Head of Manufacturing at Peninsula Laboratories in San Carlos, California from 2001 to 2004.
Dr. Yann Samson, Chairman of the Supervisory Board of Medios AG, emphasized the strategic importance of this appointment, stating that Meier's track record of capital-efficient, profitable growth aligns with Medios' ambitious goals. The company, which operates across Germany, the Netherlands, Belgium and Spain, aims to strengthen its pioneering role in making innovative therapies accessible through partnerships with pharmacies, specialist practices and pharmaceutical companies.
Meier's appointment signals Medios' commitment to accelerating its growth strategy in the competitive European pharmaceutical landscape. As Germany's first listed specialty pharmaceutical company, with shares traded on the Frankfurt Stock Exchange Prime Standard and included in the SDAX selection index, leadership stability and strategic direction are crucial for maintaining investor confidence and market position.
The transition comes during a period of significant activity for Medios, with important financial communications scheduled including the Quarterly Statement as of September 30, 2025, and participation in key industry conferences. Investors and industry observers can monitor the company's progress through its corporate communications at https://www.medios.group and learn more about their specialized medical approaches at https://app.medios.group/en/individualizedmedicine.
For patients and healthcare providers across Europe, this leadership change represents Medios' continued focus on advancing individualized medicine, ensuring that innovative treatments reach those who need them through efficient supply chain solutions. The company's specialized approach to pharmaceutical distribution supports the broader healthcare ecosystem by connecting cutting-edge therapies with medical professionals and patients.
